Definitive Healthcare Corp. (NASDAQ:DH) Short Interest Down 6.2% in April

Definitive Healthcare Corp. (NASDAQ:DH) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 6,980,000 shares, a decline of 6.2% from the March 31st total of 7,440,000 shares. Currently, 14.4% of the company’s stock are sold short. Based on an average daily trading volume, of 522,800 shares, the days-to-cover ratio is currently 13.4 days.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its position in shares of Definitive Healthcare by 599.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after buying an additional 4,959 shares during the period. Norden Group LLC acquired a new position in shares of Definitive Healthcare during the first quarter worth approximately $83,000. Berry Wealth Group LP acquired a new stake in Definitive Healthcare in the first quarter worth approximately $99,000. Reynders McVeigh Capital Management LLC acquired a new stake in Definitive Healthcare in the fourth quarter worth approximately $129,000. Finally, Arizona State Retirement System lifted its position in Definitive Healthcare by 13.6% in the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock worth $142,000 after purchasing an additional 1,701 shares during the period. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Stock Performance

Shares of DH stock opened at $6.97 on Thursday. The company has a quick ratio of 2.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.20. The business has a 50 day moving average of $7.94 and a two-hundred day moving average of $8.30. Definitive Healthcare has a 52 week low of $5.53 and a 52 week high of $12.45. The company has a market cap of $820.99 million, a P/E ratio of -3.92, a PEG ratio of 6.23 and a beta of 1.39.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.02). The business had revenue of $65.93 million for the quarter, compared to analyst estimates of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. As a group, analysts anticipate that Definitive Healthcare will post 0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

DH has been the subject of several research analyst reports. Canaccord Genuity Group boosted their price objective on Definitive Healthcare from $9.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, February 29th. Needham & Company LLC lowered Definitive Healthcare from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Canaccord Genuity Group lowered Definitive Healthcare from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Barclays boosted their price objective on Definitive Healthcare from $10.00 to $11.00 and gave the company an “equal weight” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus decreased their target price on Definitive Healthcare from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 17th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.31.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.